Vimta Labs is in the business of contract research and
testing for the pharmaceutical industry.
The company has received national and international
accreditations, been subject to audits by global regulators, and entered into
partnerships with market leaders in the past.
It reported stable operating profits on steadily growing
revenues until the last twelve months – when it reported marginal operating
losses (instead of the usual profits before depreciation of 20 to 25cr) on
revenues of about 90cr, primarily due to delays in approvals (see below) and
increased costs of materials consumed in its operations.
The company’s debt load is high relative to recent cash
flows and is largely dependent on collection of its receivables to pay it
off. It is therefore exposed to high
interest rates as well as a depreciating INR in paying its domestic and foreign
currency loans respectively.
The auditors’ report revealed that the company has, in fact,
defaulted in repayment of few of the instalments of the loans it owes – as suspected
above. This situation is unlikely to
change unless receivables are collected in a timely manner and the below risks
are mitigated in an effective manner.
The business is exposed to severe delays in receiving
regulatory approvals for projects. It is
also subject to heavy competition from multi-national companies looking for a
low cost base.
The business, by its very nature, requires continuous
innovation in portfolios which precludes the building of sustainable
competitive edge. It also requires
investments based on foresight – sometimes years in advance – that are subject
to considerable risk of error.
Apart from the above, the business is exposed to changes in
government regulations, high employee turnover in a rapid growth environment,
and inflationary cost increases among other factors.
Comments
Post a Comment